Nanosomal Amphotericin B is an efficacious alternative to Ambisome® for fungal therapy

International Journal of Pharmaceutics

Volumn 397, Issue 1-2, 2010, Pages 103-108

  Sheikh, Saifuddin ^a   Ali, Shoukath M ^a   Ahmad, Moghis U ^a   Ahmad, Ateeq ^a   Mushtaq, Mohammad ^b   Paithankar, Mahesh ^c   Mandal, Jayanta ^c   Saptarishi, Dipak ^c   Sehgal, Ashish ^c   Maheshwari, Kirti ^c   Ahmad, Imran ^a  

^a Jina Pharmaceuticals Inc   (United States)

^b Nia Life Sciences Inc   (United States)

^c Astron Research Limited   (India)

Author keywords

Amphotericin B; Antifungal; Formulation; Lipids; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; CREATININE; EXCIPIENT; GLUCOSE; LIPID; NANOSOMAL AMPHOTERICIN B; NITROGEN; PHOSPHATIDYLCHOLINE; SODIUM CHOLESTERYLSULFATE; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EXPERIMENTAL RABBIT; FEMALE; HEMOLYSIS; HUMAN; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SURVIVAL; TRANSMISSION ELECTRON MICROSCOPY; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; FEMALE; LIPOSOMES; MALE; MICE; MICE, MUTANT STRAINS; NANOPARTICLES; RABBITS;

EID: 77955981142     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.07.003     Document Type: Article

References (20)

1. Ahmad I., Sarkar A.K., Bachhawat B.K. Design of liposomes to improve delivery of amphotericin B in the treatment of aspergillosis. Mol. Cell. Biochem. 1989, 91:85-90.
2. Ahmad I., Sarkar A.K., Bachhawat B.K. Effect of cholesterol in various liposomal compositions on the in vivo toxicity, therapeutic efficacy, and tissue distribution of Amphotericin-B. Biotechnol. Appl. Biochem. 1990, 12:550-556.
3. Ahmad I., Sarkar A.K., Bachhawat B.K. Liposomal amphotericin-B as a therapeutic measure to control experimental aspergillosis in BALB/c mice. Indian J. Biochem. Biophys. 1990, 27:370-374.
4. Ahmad I., Sarkar A.K., Bachhawat B.K. Mannosylated liposome-mediated delivery of Amphotericin-B in the control of experimental aspergillosis in BALB/c mice. J. Clin. Biol. Nutr. 1991, 10:171-179.
5. Ahmad I., Agarwal A., Pal A., Guru P.Y., Bachhawat B.K., Gupta C.M. Tissue distribution and antileishmanial activity of liposomised Amphotericin-B inBALB/c mice. J. Biosci. 1991, 14:217-221.
6. Ahmad I., Perkins W.R., Lupan D.M., Selsted M.E., Janoff A.S. Liposomal entrapment of the neutrophil-derived peptide indolicidin endows it with in vivo antifungal activity. Biochim. Biophys. Acta 1995, 1237:109-114.
7. Ambisome®, Clinical and Pharmacological Profile, Package insert, Astellas Pharma, October, 2008.
8. Amphocil™/Amphotec®, Patient Information Leaflet, Three River Pharmaceuticals, July, 2005.
9. Andrews F.A., Beggs W.H., Sarosi G.A. Influence of antioxidants on the bioactivity of Amphotericin B. Antimicrob. Agents Chemother. 1977, 11:615-618.
10. Brajtburg J., Bolard J. Carrier effects on biological activity of Amphotericin-B. Clin. Micro. Rev. 1996, 9:512-531.
11. Crof S.L., Davidson R.N., Thornton E.A. Liposomal Amphotericin B in the treatment of visceral leishmaniasis. J. Antimicrob. Agents 1991, 28:111-118.
12. Gates C., Pinney R.J. Amphotericin B and its delivery by liposomal and lipid formulations. J. Clin. Pharm. Ther. 1993, 18:27-38.
13. Gregoriadis G. Overview of liposomes. J. Antimicrob. Chemother. 1987, 28:39-48.
14. Larabi M., Pages N., Pons A.M., Gulik A., Schlatter J., Bouvet S., Barratt G. Study of the toxicity of a new lipid complex formulation of amphotericin B. J. Antimicrob. Chemother. 2004, 53:81-88.
15. Lanternier F., Lortholary O. Liposomal amphotericin B: what is its role in 2008?. Clin. Microbiol. Infect. 2008, 14:71-83.
16. Moonis M., Ahmad I., Bachhawat B.K. Effect of elimination of phagocytic cells by liposomal dichloromethylene diphosphonate on Aspergillosis virulence and toxicity of liposomal amphotericin B in mice. J. Antimicrob. Chemother. 1994, 33:571-583.
17. Ostrosky-Zeichner L., Marr K.A., Rex J.H., Cohen S.H. Amphotericin B: time for a new " Gold Standard" Rev. Anti-infect. Agent 2003, 37:415-425.
18. Swenson C.E., Perkins W.R., Roberts P., Ahmad I., Stevens R., Steven D.A., Janoff A.S. In vitro and in vivo antifungal activity of Amphotericin B lipid complex: are phospholipase important? 1998, 42:767-771.
19. Storm G., Woodle M.C. Long circulating liposome therapeutics: from concept to clinical reality. Long Circulating Liposomes: Old Drugs, New Therapeutics 1998, 3-16. Springer-Verlag, New York. M.C. Woodle, G. Storm (Eds.).
20. Szoka F.C., Milholland D., Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. J. Clin. Pharm. Ther. 1987, 18:27-38.